Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Arm, Phase 2 Study
J Thorac Oncol 2023 Feb 02;[EPub Ahead of Print], X Hou, C Zhou, G Wu, W Lin, Z Xie, H Zhang, J Yi, Z Peng, L Yin, C Ma, L ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.